Last reviewed · How we verify

Aczone 5% gel — Competitive Intelligence Brief

Aczone 5% gel (Aczone 5% gel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfone antimicrobial agent. Area: Dermatology.

marketed Sulfone antimicrobial agent Bacterial dihydropteroate synthase; anti-inflammatory mechanisms Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Aczone 5% gel (Aczone 5% gel) — Derm Research, PLLC. Dapsone reduces inflammation and bacterial growth in acne lesions through antimicrobial and anti-inflammatory effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aczone 5% gel TARGET Aczone 5% gel Derm Research, PLLC marketed Sulfone antimicrobial agent Bacterial dihydropteroate synthase; anti-inflammatory mechanisms

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfone antimicrobial agent class)

  1. Derm Research, PLLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aczone 5% gel — Competitive Intelligence Brief. https://druglandscape.com/ci/aczone-5-gel. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: